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Background. Limited information exists on long-term prognosis of patients with sustained virologic response to antiretroviral
therapy. We aimed to assess predictors of unfavorable clinical outcome in patients who maintain viral suppression with
HAART. Methods. Using data collected from ten clinic-based cohorts in Spain, we selected all antiretroviral-naive adults who
initiated HAART and maintained plasma HIV-1 RNA levels ,500 copies/mL throughout follow-up. Factors associated with
disease progression were determined by Cox proportional-hazards models. Results. Of 2,613 patients who started HAART, 757
fulfilled the inclusion criteria. 61% of them initiated a protease inhibitor-based HAART regimen, 29.7% a nonnucleoside
reverse-transcriptase inhibitor-based regimen, and 7.8% a triple-nucleoside regimen. During 2,556 person-years of follow-up,
22 (2.9%) patients died (mortality rate 0.86 per 100 person-years), and 40 (5.3%) died or developed a new AIDS-defining event.
The most common causes of death were neoplasias and liver failure. Mortality was independently associated with a CD4-T cell
response ,50 cells/L after 12 months of HAART (adjusted hazard ratio [AHR], 4.26 [95% confidence interval {CI}, 1.68–10.83];
P=.002), and age at initiation of HAART (AHR, 1.06 per year; 95% CI, 1.02–1.09; P=.001). Initial antiretroviral regimen chosen
was not associated with different risk of clinical progression. Conclusions. Patients with sustained virologic response on
HAART have a low mortality rate over time. Long-term outcome of these patients is driven by immunologic response at the
end of the first year of therapy and age at the time of HAART initiation, but not by the initial antiretroviral regimen selected.
Citation: Gutierrez F, Padilla S, Masia ´ M, Iribarren JA, Moreno S, et al (2006) Clinical Outcome of HIV-Infected Patients with Sustained Virologic
Response to Antiretroviral Therapy: Long-Term Follow-Up of a Multicenter Cohort. PLoS ONE 1(1): e89. doi:10.1371/journal.pone.0000089
INTRODUCTION
In the majority of drug-naive patients, initiation of highly active
antiretroviral therapy (HAART) results in a reduction in plasma
virus load (pVL) to below the detection limit of currently available
assays [1]. Plasma viremia is a strong prognostic indicator of HIV
disease progression [2–5], and suppression of pVL as much as
possible for as long as possible has become the primary aim of
antiretroviral therapy at present [6]. Long-term suppression of
virus replication is expected to ensure recovery of CD4 T-cell
numbers enough to protect against opportunistic infections and
hence continuous treatment benefit. While several cohort studies
have confirmed the overall long-term effectiveness of potent
antiretroviral therapy [7–11], limited information exists on clinical
outcomes and predictors of disease progression in the setting of
constant pVL suppression, an scenario that is becoming in-
creasingly common in HIV medicine.
In the present study, we describe clinical outcomes and analyze
predictors of disease progression in patients with sustained viral
suppression from a large multicenter observational cohort
constituted after HAART availability.
METHODS
Study population and definitions
This project is a joint activity of a recently created Research
Network of Excellence (AIDS research network, RIS) funded by
the Spanish Research Council which incorporates basic scientists,
immunologists, virologists, clinicians, epidemiologists and statisti-
cians. A total of 10 HIV clinic-based cohorts from 7 of the 17
Autonomous Communities of the country (see appendix) partic-
ipate in the project. Data were collected during the course of
clinical care of HIV patients at cohort sites from January 1, 1997
through December 31, 2003. The cohort characteristics have been
previously described in detail elsewhere [12]. Each center
provided a set of pre-defined variables in a convertible electronic
format. The set of variables included the following: gender, date of
birth, most probable route of HIV infection, date of first confirmed
HIV positive result in the recruiting centre, AIDS defining
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age at HAART initiation, antiretroviral drugs and regimens
prescribed and dates of initiation and finalization, CD4 cell count
and pVL values in successive visits as well as dates of
measurement, vital status, and date of death. CD4 cell count
and pVL measurements were performed by the clinical labora-
tories associated with each of the participating sites. CD4 cell
counts were assessed by flow cytometry. Plasma HIV RNA levels
were measured by a commercial quantitative PCR technique
(Amplicor HIV [Roche Diagnostic Systems], or branched-chain
DNA amplification assay [Chiron Diagnostics]). With the data
obtained we defined a cohort of patients over 18 years of age that
had at least 6 months of follow-up. Censoring date for the analyses
was December 31, 2003. Data were cross-checked with the
National AIDS Registry in September 2004. Losses to follow-up
were calculated by estimating the percentage of subjects still alive,
which had not been seen in the clinics in the 12 months previous to
December 31, 2003.
For the purpose of these analyses, we selected all antiretroviral-
naive patients who began HAART (i.e., any combination of 3
antiretroviral drugs, including at least 1 protease inhibitor [PI], 1
nonnucleoside reverse-transcriptase inhibitor [NNRTI], or aba-
cavir) since January 1, 1997. Patients were included in the analyses
if they met all the following criteria: 1) pre-HAART CD4 cell
count of ,350 cells/mL and plasma virus load .1000 copies/mL,
2) $6 months of follow-up and at least one determination of CD4
cell count and pVL after HAART initiation, 3) a complete
virologic response to therapy, defined as maintained virus
suppression (pVL below 500 HIV-1 RNA copies/mL) throughout
follow-up, and 4) a pVL confirming virologic suppression
(,500 HIV-1 RNA copies/mL) within 6 months of the last
database update. This value of 500 HIV-1 RNA copies/mL was
chosen to overcome the heterogeneity of the assay detection limits
used to quantify plasma HIV RNA during the study period in the
different medical centres.
The last available CD4 cell count obtained within the 2 months
before the start of HAART was termed the pre-HAART CD4 cell
count. CD4-T cell responses were defined according to changes in
CD4 cell count from the pre-HAART value to 6 months (62
months) and 12 months (62 months) after HAART initiation. A
‘‘low’’ CD4-T cell response to HAART was defined as an increase
in CD4 cell count ,50 cells/mL from the pre-HAART assess-
ment. This cut-off has been previously used in other studies [13–
16]. AIDS-defining events (ADE) were defined according to the
1993 revised clinical definition of the Centers for Disease Control
and Prevention. Reported deaths were investigated for their cause
by review of the medical chart.
Statistical analyses
Outcome measures were deaths and new ADE (i.e. CDC stage C)
that occurred after the first 6 months of HAART. Patients who
developed a new AIDS disease during follow-up were included
only once; recurrences were not considered. The primary
endpoint was all cause mortality. We also conducted sub-analyses
of nonaccidental mortality (excluding deaths attributable to
trauma), and of progression to a new ADE or nonaccidental death.
Univariate analyses were performed by using Kaplan-Meier
estimates, and differences between curves were tested by using the
log-rank tests. For multivariate analysis, we used Cox pro-
portional-hazards models to determine the factors associated with
outcome measures. age, gender, category of transmission, previous
AIDS diagnosis, pre-therapy CD4 cell count, pre-therapy pVL,
type of HAART combination and CD4-T cell responses to
HAART, as defined above, were evaluated as potential predictors
of clinical outcome. Age at HAART initiation was analysed as
a continuous variable and dichotomized into two groups (,50
years and $50 years). This age cut-off is commonly used in other
studies [17,18]. HAART regimens were classified as follows: non-
boosted PI-based (a combination of nucleoside reverse transcrip-
tase inhibitors [NRTI] plus any of the following PI: nelfinavir,
indinavir, saquinavir or ritonavir), boosted PI-based (a combina-
tion of NRTI plus any ritonavir boosted PI), NNRTI-based (a
combination of NRTI plus either nevirapine or efavirenz), and
nucleoside/nucleotide-based regimens (a combination of 3 or
more nucleoside/nucleotides). For the purposes of this analysis we
followed the ‘‘intent-to-continue-treatment’’ approach and thus
ignored subsequent changes of treatment, including treatment
interruptions and terminations. All variables with a P,0.1 in the
univariate analysis were tried to enter simultaneously in a multi-
variate Cox model. Patients not known to be dead by December
31, 2003 were censored on the date they were last known to be
alive. SPSS (version 11) was used for data management and
statistical analysis. A two-tailed P value of 0.05 or less was
considered significant.
RESULTS
Patients characteristics at baseline
The cohort database contained data on 4643 patients with at least
6 months of follow-up. Of these, 73% were men and the median
age was 35 (interquartile range [IQR], 31–39) years. Overall,
56.4% were intravenous drug users, 22.6% heterosexuals and
14.4% men who had sex with men. Twenty-one percent were
diagnosed of AIDS prior to study entry. The incidence rate of
AIDS during follow-up was 3.6 per 100 person-years. Overall, 310
(6.7%) patients died, being the death rate 1.7 per 100 person-
years. Twenty-seven percent had started HAART prior to study
entry. Of the 3421 treatment-naive subjects, 2613 started HAART
during follow-up.
A total of 757 patients fulfilled the inclusion criteria and they
were, therefore, eligible for the present analyses. Baseline
demographic and clinical characteristics of the patient sample
are shown in table 1.
Antiretroviral therapy, CD4-T cell responses and
outcome
Antiretroviral therapy administered is detailed in table 2. Sixty one
percent of the patients initiated a PI-based HAART regimen
(45.3% a non-boosted PI regimen and 15.9% a boosted PI
regimen), and 29.7% initiated a NNRTI-based HAART regimen.
Only 59 patients (7.8%) started a triple-nucleoside regimen.
Median follow up period was 3.1 years (IQR, 1.62–5.01). A
total of 63 (8.3%) subjects were lost to follow-up. Lost to follow-up
patients were younger (median age [IQR], 34.86 [31.08–38.21]
versus 37.26 [33.95–42.49] years; P,0.000), and were more likely
to be intravenous drug users (62.3% versus 47.7%; P=0.029), but
did not differ with respect to baseline pVL, baseline CD4 cell
counts, prevalence of AIDS at baseline, or immunological
responses at 6 and 12 months of HAART initiation.
CD4- T cells increased in the entire patient sample from a mean
of 162 (SD, 103) cells/mL before starting HAART, to 302 (SD,
176) cells/mL and 346 (SD, 176) cells/mL, at 6 and 12 months,
respectively, after the initiation of HAART (P,0.001). According
to previous definition, 180 (24.9%) of the 722 patients with CD4
cell counts available at 6 months had a ‘‘low’’ CD4-T cell
response. At 12 months, data were available for 650 (85.9%)
patients, with 108 (16.6%) showing a ‘‘low’’ CD4-T cell response
Outcome HIV Patients
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(mortality rate 0.86 per 100 person-years), 21 (95.4%) of them
were nonaccidental deaths. A total of 21 (2.8%) subjects
experienced a new ADE, and 40 (5.3%) developed an ADE or
death throughout follow-up. Of the 21 nonaccidental deaths,
analysis of cause-specific mortality indicated that 7 (33.3%)
patients died of neoplasias [lymphoma, 4 cases; non-AIDS-
defining cancers (lung 1, pancreas 1, colon 1), 3 cases]; 4 (19%)
patients died of liver failure and/or cirrhosis; 4 (19%) of
opportunistic or bacterial infections (pneumonia or sepsis 2,
disseminated tuberculosis 1, progressive multifocal leukoencepha-
lopathy 1), 1 (4.8%) case from progressive end-organ disease
(cardiac and renal), and 1 case committed suicide. Despite
a thorough review, cause of death could not be ascertained for
the remaining 4 (19%) individuals who died away from the
hospital; in all of them the death was sudden and unexpected.
Predictors of clinical outcome
Cox models were constructed to investigate factors associated with
death and development of an ADE after 6 months of HAART
initiation (Table 3). Factors associated with death in the univariate
model were age at HAART initiation (hazard ratio [HR], 1.06 per
year; 95% confidence interval {CI}, 1.02–1.09), and low CD4-T
cell response at 12 month of HAART initiation (HR, 4.81; 95%
CI, 1.77–11.36). In the multivariate models, both factors remained
associated with disease progression. When age was entered in the
model dichotomized into two groups (,50 years and $50 years),
age $50 years at HAART initiation (adjusted hazard ratio
[AHR], 3.19, 95% CI; 1.13–09.01; P=0.029), and low CD4-T
cell response at 12 month (AHR, 4.26; 95% CI, 1.68–10.83;
P=0.002) were independently associated with mortality (Table 3).
When new ADE or death was modelled as the outcome, the 2
same factors remained associated in the multivariate analysis.
When age was entered in the model dichotomized, age $50 years
(AHR, 2.94, 95% CI; 1.37–6.33; P=0.006), and low CD4-T cell
response at 12 month (AHR, 2.45; 95% CI, 1.19–5.03; P=0.015)
were independent predictors of new ADE or death (Table 3).
The results were unchanged when either nonaccidental
mortality or new ADE or nonaccidental mortality were modelled
as the outcome (data not shown).
At Kaplan–Meier estimates, a significant difference was found
in terms of proportion of patients experiencing death, and new
AIDS defining event or death, during the follow-up period
according to CD4-T cell response, and age at HAART initiation
(,50 years versus $50 years) (Figure 1).
DISCUSSION
The study has confirmed that patients with sustained virologic
response to HAART have a very low mortality rate over time. The
analyses have shown that low CD4-T cell responses at 12 months
and age at the initiation of antiretroviral therapy are the main
determinants of unfavourable long-term outcome. The initial
antiretroviral regimen chosen, however, was not associated with
different risk of clinical progression. Our results are based on
a large population of patients with over 2500 patient-years of
observation, which allowed us to examine clinical progression up
Table 1. Demographic and clinical characteristics of patients included in the analysis (n=757).
..................................................................................................................................................
Characteristics Values
Male gender, no. (%) 563 (74.4)
Age at entry, median years (IQR) 37.14 (33.68–41.95)
HIV transmission category, no. (%)
Intravenous drug user 347 (45.8)
Heterosexual contact 221 (29.2)
Men who have sex with men 114 (15.1)
Other/Unknown 75 (9.9)
Pre-therapy AIDS status (%)
No AIDS 506 (66.8)
AIDS 251 (33.2)
Pre-therapy CD4 cell count (610
6 cells/L), median (IQR) 160 (65–250)
Pre-therapy plasma HIV RNA level (log10 copies/mL), median (IQR) 5.00 (4.36–5.38)
CD4 cell count at 6 months (610
6 cells/L), median (IQR) 270 (172–400)
CD4 cell count at 12 months (610
6 cells/L), median (IQR) 319 (212–452)
Low CD4 T-cell response at 6 months, no. (%)
a 180 (24.9)
Low CD4 T-cell response at 12 months, no. (%)
a 108 (16.6)
Follow up, median years (IQR) 3.10 (1.62–5.01)
Deaths, no. (%) 22 (2.9)
New AIDS-defining event after 3 months of HAART, no. (%) 21 (2.8)
Death or new AIDS-defining event, no. (%) 40 (5.3)
AIDS incidence, per 100 person-years 0.82
Death rate, per 100 person-years 0.86
NOTE. (%) means percentage of patients showing this characteristic out of the total number of patients included (n=757); IQR, interquartile range; HAART, highly active
antiretroviral therapy;
aDefined as CD4 cell count increase ,50 cells/L from the pre-HAART value.
doi:10.1371/journal.pone.0000089.t001
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PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e89to more than 3 years after starting HAART. The cohort includes
many clinics treating HIV-1-infected patients from different
regions of Spain, with a broad spectrum of patient characteristics
and antiretroviral regimens. The results should therefore be
applicable to many individuals with HIV-1 infection beginning
HAART in Spain and elsewhere.
Low immunological response to antiretroviral therapy was the
strongest predictor of mortality. This finding is in agreement with
those from previous studies assessing clinical outcomes in patients
receiving HAART, that have suggested poorer prognosis in
subjects with discordant immunologic and virologic responses
[13,15,19–22]. Most of these studies have investigated responses to
HAART at 6–9 months, defined as either absolute values attained
[21] or increase in CD4 cell counts of at least 25 cells/mL [22] or
50 cells/mL from baseline [13,15,21]. Immunologic responses of
50 cells/mL had previously been correlated with a reduced risk for
the development of opportunistic infections [14]. Our results give
support to the prognostic significance of this threshold, and are in
accordance with recent data by investigators from British
Columbia [15] analyzing data from 1527 treatment-naive
individuals initiating HAART. In that cohort, failure to gain
50 cells/mL from baseline within 3 to 9 months after initiating
HAART was found to be a significant predictor of later mortality
in patients with virologic suppression. In our study, however, the
response at 6 months was less predictive of clinical outcome than
that measured after 12 months of HAART initiation.
In addition to suboptimal immunological response, older age at
initiation of HAART was found to predict unfavorable outcome in
our study. Most studies have shown that compared with younger
patients, patients over 50 generally have a slower immunological
response to HAART and experience more rapid clinical pro-
gression [17,23]. However, in our study the detrimental effect of
age on progression to a new AIDS defining event or death
persisted after adjusting for CD4-T cell response, suggesting that
age contributes independently to clinical progression.
Several published randomized clinical trials have shown that
different antiretroviral regimens have different capacities to
decrease the pVL and raise the CD4 cell count thus leading to
different clinical efficacy. In addition, it has been suggested that
antiretroviral drugs might have effects on risk of AIDS and/or
death, which are not mediated by their effect on HIV-RNA and
CD4 cell count [24,25]. In this cohort of patients with sustained
virologic response on HAART, however, the initial antiretroviral
regimen chosen was not associated with different risk of clinical
progression. This finding is in agreement with the results of
a recent analysis from the EuroSIDA observational cohort
indicating that AIDS/death rates for given CD4 cell count and
pVL categories are similar, independently of HAART regimen
[26].
An expected finding from the study was the significant
contribution of mortality from non-AIDS-defining illnesses,
including cancer and end-stage liver disease. These results
corroborate previous findings that indicate that the relative
proportion of non-AIDS-related death has increased during the
period of HAART [27], and that patients with AIDS are now
experiencing growing mortality from causes generally referred to
as non-HIV-related [28–31]. Although some of these deaths may
be the result of a number of factors including common
comorbidities that occur in patients with AIDS, a relationship to
immunodeficiency can not be ruled out. A recent analysis from the
D:A:D cohort has shown that deaths from causes generally
supposed to be unrelated to HIV, such as liver-related deaths and
deaths from non-AIDS malignancies, were in fact more likely to
occur in persons with low CD4 cell counts, indicating that both
HIV-related and ‘‘non-HIV-related’’ mortality may be associated
with immunodeficiency [32].
A number of limitations in our study should be noted. First, to
be included in the analysis, patients recorded in the database must
have had at least a CD4 cell count and pVL assessment within 6 to
12 months after starting HAART. As a result, patients who died or
were lost to follow-up before a second CD4 cell count assessment
were not included, and consequently the risk for clinical
progression may have been underestimated. The 8% losses to
follow-up could have introduced a number of other different biases
into our results. Lost to follow-up patients were younger and they
were more likely to be intravenous drug users. However,
considering the total number of losses and the lack of differences
in other baseline parameters, including immunological responses
to HAART, with respect to the other group, the effect of such
biases would likely to be small. The analyses of the effect of
different antiretroviral regimens is limited by the fact that it was
a nonrandomized, observational cohort study, and the selection of
Table 2. Antiretroviral therapy administered to patients
included in the analysis (n=757).
......................................................................
Type of antiretroviral therapy n (%)
HAART regimen
Non-boosted PI 343 (45.3)
Nelfinavir 153
Indinavir 140
Ritonavir 31
Saquinavir 15
Double non-boosted PI 4
Boosted PI 120 (15.9)
Lopinavir-ritonavir 66
Indinavir-ritonavir 41
Saquinavir-ritonavir 2
Other combinations 11
NNRTI 225 (29.7)
Efavirenz 174
Nevirapine 48
Efavirenz plus nevirapine 3
PI+NNRTI 10 (1.3)
NRTI without PI or NNRTI 59 (7.8)
AZT+3TC+ABC 44
Other combinations of NRTI 15
NRTI used in the backbone
AZT+3TC 338 (44.6)
D4T+3TC 210 (27.7)
AZT+3TC+ABC 57 (7.5)
D4T+DDI 48 (6.3)
DDI+3TC 19 (2.5)
ABC+3TC 14 (1.8)
AZT+DDI 10 (1.3)
Other 61 (8.0)
NOTE. (%) means percentage of patients showing this characteristic out of the
total number of patients included (n=757); HAART, highly active antiretroviral
therapy; PI, protease inhibitor; NNRTI, non nucleoside reverse-transcriptase
inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; AZT, zidovudine; 3TC,
lamivudine; ABC, abacavir; D4T, stavudine; DDI, didanosine.
doi:10.1371/journal.pone.0000089.t002
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availability of the antiretroviral drugs throughout the study.
Finally, given the large number of participating sites, variations in
CD4 cell counts and pVL might have occurred. A potential impact
of such variations on the study results cannot be ruled out.
Several confounding factors might have influenced the results.
Unfortunately, hepatitis C virus (HCV) serostatus and adherence
to therapy were not included among the set of pre-defined
variables in the database, therefore the contribution of these
factors to immunological response and clinical outcomes could not
be ascertained in the study. The influence of HCV co-infection in
immunological response to HAART remains controversial. Re-
cent data from the British Columbia cohort suggest that HCV
antibody-positive HIV-infected patients may have an altered
immunologic response to HAART [33], a finding that has not
been confirmed by EuroSIDA study group [34]. Although
adherence to therapy has previously been shown to be an
important determinant of mortality in HIV-positive individuals on
HAART [35,36], our study population maintained successful
virologic suppression throughout the follow-up, thus minimizing
the importance of this factor in our analyses.
Despite the limitations, the study represents some of the first
substantial body of data on long-term outcome of patients with
sustained virologic response on HAART. The analyses were
conduced in patients who started therapy with a broad spectrum
of antiretroviral drugs and we selected the CD4 threshold at which
antiretroviral therapy is currently recommended [6]. The results
should therefore be generalizable to many patients beginning
HAART today.
In summary, our results indicate that clinical outcome of
patients who maintain a durable virologic suppression on HAART
could be driven by the immunologic response at 12 months and
the age at the time of HAART initiation, but not by the initial
antiretroviral regimen chosen. The fact that the CD4-T cell
response is strongly associated with long-term clinical outcome
indicates that both immunologic and virologic responses are
Figure 1. Kaplan-Meier curves of progression in patients with sustained virologic response to HAART, according to CD4-T cell response and age at
HAART initiation. (a) Progression to death according to CD4-T cell response; (b) progression to death according to age at HAART initiation; (c)
progression to death or new AIDS-defining event according to CD4-T cell response, and (d) progression to death or new AIDS-defining event
according to age at HAART initiation.
doi:10.1371/journal.pone.0000089.g001
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PLoS ONE | www.plosone.org 6 December 2006 | Issue 1 | e89important when assessing the effectiveness of antiretroviral drugs.
The study results suggest the need for alternative strategies to
amend immune response in patients with low CD4-T cell increases
at the end of the first year of therapy. Older age at initiation of
HAART was also found to predict unfavorable outcome,
indicating that age at which therapy is started should be carefully
considered.
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